Composition for reducing homocysteine and preparation method thereof

Abstract

The embodiment of the invention discloses a composition for reducing homocysteine and a preparation method thereof, and belongs to the technical field of homocysteine reduction. The composition is prepared from the following raw materials in parts by weight: 1300 to 1800 parts of betaine, 80 to 90 parts of zinc gluconate, 14 to 18 parts of vitamin B2, 6 to 10 parts of vitamin B6, 0.1 to 1 part of calcium 6s-5-methyltetrahydrofolate, 0.001 to 0.01 part of vitamin B12, 1 to 6 parts of taurine, 2 to 4 parts of rice bran fatty alkanol, 3 to 7 parts of vitamin B13 and 0.001 to 0.01 part of cystathionine-beta-synthetase. The composition provided by the invention can comprehensively dredge an Hcy metabolic channel, and the Hcy metabolic channel is converted into methionine, namely methionine through a remethylation way; the method comprises the following steps: synthesizing cystathionine from Hcy and serine under the catalysis of cystathionine-beta-synthetase through a sulfuration transfer pathway, then splitting the cystathionine under the action of cystathionine-gamma-lyase and coenzyme vitamin B6 to generate cysteine, and further participating in synthesis of glutathione or directly discharging the cysteine out of a body through urine.

Description

Technical Field

[0001] The embodiments of the present invention relate to the technical field of reducing homocysteine, and particularly to a composition for reducing homocysteine ​​and a preparation method thereof. Background Art

[0002] Homocysteine ​​(Hcy) is a sulfur-containing amino acid and an intermediate product in the metabolism of methionine. In recent years, research on Hcy has become increasingly in-depth, and it has become one of the hot research areas in modern basic medicine, nutrition and clinical medicine. At present, the medical community generally agrees that there is a correlation between Hcy levels and a variety of diseases. High Hcy levels can damage vascular endothelial cells, promote the proliferation of vascular smooth muscle cells, affect lipid metabolism, increase the adhesion of platelets in the blood, and destroy the balance of coagulation and fibrinolysis in the body, thereby increasing the risk of cardiovascular and cerebrovascular diseases such as heart disease and stroke. At the same time, Hcy is also closely related to hypertension, and the two promote each other and jointly increase the risk of cardiovascular disease. High Hcy levels can also accelerate the oxidation process of the brain, damage brain cells, affect the normal function of the brain, and lead to problems such as memory loss and decreased intelligence. Hcy may also cause serious health problems such as epilepsy, dementia, and mental illness.

[0003] In addition, elevated Hcy levels can aggravate insulin resistance, increase the risk of diabetes, and aggravate the symptoms of diabetes. Elevated Hcy levels can induce DNA hypomethylation and disrupt the body's oxidation / reduction system, placing the body in a state of high oxidative stress, thereby promoting the occurrence and development of tumors and increasing the risk of tumors. Hyperhomocysteinemia is closely related to kidney disease and can lead to diseases such as renal insufficiency and renal failure. Hyperhomocysteinemia (HHcy) increases the risk of diseases such as pregnancy-induced hypertension (PIH), gestational diabetes (GDM), intrahepatic cholestasis of pregnancy (ICP), and gestational thrombosis, and may have a negative impact on fetal nervous system development, growth, hypoxia, congenital malformations, and premature birth.

[0004] At present, the medical community generally uses drugs to reduce the Hcy content in the blood. However, these drugs are often ineffective and have side effects. Therefore, it is very important to develop a safe, effective, side-free product that can fully dredge the Hcy metabolic channel to solve this problem. Summary of the invention

[0005] To this end, the present invention provides a composition for reducing homocysteine ​​and a preparation method thereof, so as to solve the problem of poor effect and side effects caused by using drugs to reduce the Hcy content in the blood in the prior art.

[0006] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:

[0007] According to a first aspect of an embodiment of the present invention, the present invention provides a composition for reducing homocysteine, wherein the composition comprises the following raw materials by weight: 1300-1800 parts of betaine, 80-90 parts of zinc gluconate, 14-18 parts of vitamin B2, 6-10 parts of vitamin B6, 0.1-1 parts of 6s-5-methyltetrahydrofolate calcium, and 100 parts of vitamin B6. 12 0.001-0.01 parts, taurine 1-6 parts, rice bran fatty alkanol 2-4 parts, vitamin B13-7 parts, cystathionine-β-synthase 0.001-0.01 parts;

[0008] The composition further comprises 180-190 parts of auxiliary materials;

[0009] The auxiliary material is selected from one or more of polyvinyl pyrrolidone, hydroxypropyl methylcellulose, magnesium stearate, sucrose, mannitol and cellulose acetate.

[0010] Among them, 5-10-methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme in the metabolism of folate and Hcy. MTHFR catalyzes the irreversible reduction of 5-10-MTHF to 5-methylTHF, a circulating form of folate used for the remethylation of Hcy to methionine.

[0011] Folic acid is reduced to tetrahydrofolate (THF), and THF combines with methyl groups in the methyl pool (composed of dimethylglycine, sarcosine, serine, etc.) to generate 5,10-methylenetetrahydrofolate, which is irreversibly converted to 5-methyltetrahydrofolate under the catalysis of 5,10-methylenetetrahydrofolate reductase.

[0012] Cystathionine-β-synthase (CβS, which uses vitamin B6 as a coenzyme): In some human bodies, CβS is deficient, which affects Hcy metabolism. In the transsulfurization pathway, Hcy and serine are synthesized into cystathionine under the catalysis of cystathionine-β-synthase. Cystathionine is then cleaved into cysteine ​​(Cys) under the action of cystathionine-γ-lyase (CSE). Cys then further participates in the synthesis of glutathione or is directly excreted from the body through urine.

[0013] Vitamin B 12 : Responsible for transferring the methyl group of 5-methyltetrahydrofolate to Hcy;

[0014] Vitamin B6: It is not only an important coenzyme in the Hcy transsulfurization pathway, but also an important coenzyme in the production of 5,10-methylenetetrahydrofolate. The transsulfurization pathway has an important physiological function in the production of cysteine ​​and its derivatives. The effect of using vitamin B6 alone in lowering blood sugar is not obvious. It has a significant synergistic effect when combined with folic acid and vitamin B12.

[0015] Rice bran fatty alkanol: Its main component is fatty alcohols extracted from rice bran (natural monohydric fatty alcohols), which are composed of unsaturated fatty acids such as linoleic acid and linolenic acid in rice bran oil. It is one of the essential fatty acids for the human body and does not contain cholesterol. It can regulate the body's cell function and metabolism, and has the effect of improving cardiovascular and cerebrovascular diseases.

[0016] Taurine: It can promote the secretion of pituitary hormones and activate pancreatic function, thereby improving the state of the body's endocrine system and regulating the body's metabolism in a beneficial way; it also has the effect of promoting the body's immunity and resisting fatigue;

[0017] Natural betaine: Natural betaine can provide 3 methyl groups to the body and is the most efficient methyl donor in the body. Its methyl relative potency is 12 to 15 times that of choline. Supplementing betaine after meals is more effective than folic acid in lowering blood ketones. In the case of MTHFR gene mutation or folic acid deficiency, supplementing betaine will play a greater role. However, folic acid has no obvious effect on high blood ketones caused by insufficient choline and betaine. Betaine can be generated from choline, which is not only safe, but also can significantly reduce blood ketones, prevent water loss in the body, maintain cell vitality, and promote health.

[0018] Combined supplementation: There is a strong relationship between folic acid, betaine and the transsulfurization pathway, which is especially evident in a low folate state. It can provide methyl donors, methyl carriers and transsulfurization coenzymes at the same time, which is beneficial for correcting abnormalities in methylation and transsulfurization.

[0019] Furthermore, the composition comprises the following raw materials by weight: 1500 parts of betaine, 87.66 parts of zinc gluconate, 16 parts of vitamin B2, 8 parts of vitamin B6, 0.451 parts of 6S-5-methyltetrahydrofolate calcium, and 0.5 parts of vitamin B6. 12 0.008 parts, taurine 3 parts, rice bran fatty alkanol 3 parts, vitamin B15 parts, cystathionine-β-synthase 0.005 parts;

[0020] The composition further comprises 187.881 parts of auxiliary materials.

[0021] Furthermore, the dosage form of the composition includes capsules and tablets.

[0022] According to a second aspect of an embodiment of the present invention, the present invention provides a method for preparing the above-mentioned composition for reducing homocysteine, the method comprising the following steps:

[0023] 1) Weigh the raw materials of the formula respectively, select and weigh the auxiliary materials of the formula, and set aside;

[0024] 2) Screen the betaine, and separate the zinc gluconate, vitamin B2, vitamin B6, 6S-5-methyltetrahydrofolate calcium, taurine, rice bran fatty alkyl alcohol, cystathionine-β-synthase, vitamin B1 and vitamin B 12 Mix them into compound raw materials and sieve them, and sieve the auxiliary materials for later use;

[0025] 3) premixing the sieved betaine with the composite raw materials to obtain mixed powder A;

[0026] 4) Mixing the mixed powder A with the sieved auxiliary materials to obtain a total mixed powder, and packaging and bottling the total mixed powder to obtain the composition for reducing homocysteine.

[0027] Furthermore, the method is carried out in a Class 100,000 clean area.

[0028] Furthermore, in step 2), the mesh number of the betaine sieved is 30-50 mesh, the mesh number of the compound raw material sieved is 60-80 mesh, and the mesh number of the auxiliary material sieved is 30-50 mesh.

[0029] Furthermore, in step 3), the weight ratio of betaine to the compound raw material in the mixed powder A is 10-15:1.

[0030] Furthermore, in step 4), the total mixed powder is bottled in oral solid pharmaceutical high-density polyethylene bottles.

[0031] The embodiments of the present invention have the following advantages:

[0032] The composition provided by the present invention can fully clear the Hcy metabolic channel and convert it into methionine (i.e., methionine) through the remethylation pathway; through the transsulfurization pathway, Hcy and serine are catalyzed by cystathionine-β-synthase to synthesize cystathionine, and cystathionine is subsequently cleaved to generate cysteine ​​under the action of cystathionine-γ-lyase and coenzyme vitamin B6. After that, cysteine ​​further participates in the synthesis of glutathione or is directly excreted from the body through urine; and Hcy can also form homocysteine ​​thiolactone through a cyclization reaction;

[0033] The composition provided by the present invention has various components in a reasonable and balanced proportion, which act synergistically with each other and conform to the dynamic balance required by human physiology. Moreover, this proportion is determined after a large number of clinical practices. Therefore, it can quickly and effectively regulate the human body without any side effects. Under the condition of the same usage amount, it has better efficacy and is more economical than other similar products. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0035] Figure 1 The plasma Hcy curves of rats in each group after 30 days provided in Test Example 1 of the present invention;

[0036] Figure 2 The liver Hcy curves of rats in each group after 30 days provided in Test Example 1 of the present invention;

[0037] Figure 3 This is a graph of the liver SAM of each group of rats after 30 days provided in Test Example 1 of the present invention. DETAILED DESCRIPTION

[0038] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0039] Zinc gluconate: molecular weight 455.7, zinc content 14.26%, equivalent to a daily zinc dosage of 12.5 mg;

[0040] 6S-5-methyltetrahydrofolate calcium: molecular weight 497.5, folic acid molecular weight 441.4. According to the molecular weight, the conversion relationship between the two is: 1 mg 6S-5-methyltetrahydrofolate calcium is equivalent to 0.8872 mg folic acid.

[0041] Example 1

[0042] This embodiment provides a composition for reducing homocysteine, the raw materials of which are: betaine 1500 mg, zinc gluconate 87.66 mg, vitamin B2 16 mg, vitamin B6 8 mg, 6S-5-methyltetrahydrofolate calcium 0.451 mg, vitamin B 12 0.008mg, taurine 3mg, rice bran fatty alkyl alcohol 3mg, vitamin B15mg, cystathionine-β-synthase 0.005mg, polyvinylpyrrolidone 187.881mg;

[0043] The preparation method of the above composition comprises the following steps:

[0044] Carry out the following steps in a Class 100,000 clean area;

[0045] 1) Weigh the raw materials of the formula respectively, select and weigh the auxiliary materials of the formula, and set aside;

[0046] 2) Pass betaine through a 30-mesh sieve, and mix zinc gluconate, vitamin B2, vitamin B6, 6s-5-methyltetrahydrofolate calcium, taurine, rice bran fatty alkyl alcohol, cystathionine-β-synthase, vitamin B1 and vitamin B 12 Mix them into compound raw materials and pass through an 80-mesh sieve, and pass the auxiliary materials through a 30-mesh sieve for later use;

[0047] 3) premixing the sieved betaine with the composite raw materials to obtain mixed powder A;

[0048] 4) Mixing the mixed powder A with the sieved auxiliary materials to obtain a total mixed powder, packaging the total mixed powder and loading it into an oral solid pharmaceutical high-density polyethylene bottle to obtain a composition for reducing homocysteine.

[0049] The composition obtained in this embodiment can fully dredge the Hcy metabolic channel and convert it into methionine and methionine through the remethylation pathway; through the transsulfurization pathway, Hcy and serine are catalyzed by cystathionine-β-synthase to synthesize cystathionine, and cystathionine is subsequently cleaved to generate cysteine ​​under the action of cystathionine-γ-lyase, and cysteine ​​further participates in the synthesis of glutathione or is directly excreted from the body through urine; and Hcy can also form homocysteine ​​thiolactone through a cyclization reaction.

[0050] Example 2

[0051] This embodiment provides a composition for reducing homocysteine, the raw materials of which are: betaine 1300 mg, zinc gluconate 80 mg, vitamin B2 14 mg, vitamin B6 6 mg, 6S-5-methyltetrahydrofolate calcium 0.1 mg, vitamin B 120.001mg, taurine 1mg, rice bran fatty alkyl alcohol 2mg, vitamin B13mg, cystathionine-β-synthase 0.001mg, hypromellose 180mg;

[0052] The preparation method of the above composition comprises the following steps:

[0053] Carry out the following steps in a Class 100,000 clean area;

[0054] 1) Weigh the raw materials of the formula respectively, select and weigh the auxiliary materials of the formula, and set aside;

[0055] 2) Pass betaine through a 50-mesh sieve, and mix zinc gluconate, vitamin B2, vitamin B6, 6s-5-methyltetrahydrofolate calcium, taurine, rice bran fatty alkyl alcohol, cystathionine-β-synthase, vitamin B1 and vitamin B 12 Mix them into compound raw materials and pass them through a 60-mesh sieve, and pass the auxiliary materials through a 50-mesh sieve for later use;

[0056] 3) premixing the sieved betaine with the composite raw materials to obtain mixed powder A;

[0057] 4) Mixing the mixed powder A with the sieved auxiliary materials to obtain a total mixed powder, packaging the total mixed powder and loading it into an oral solid pharmaceutical high-density polyethylene bottle to obtain a composition for reducing homocysteine.

[0058] Example 3

[0059] This embodiment provides a composition for reducing homocysteine, the raw materials of which are: betaine 1800 mg, zinc gluconate 90 mg, vitamin B2 18 mg, vitamin B6 10 mg, 6S-5-methyltetrahydrofolate calcium 1 mg, vitamin B 12 0.01mg, taurine 6mg, rice bran fatty alkyl alcohol 4mg, vitamin B17mg, cystathionine-β-synthase 0.01mg, magnesium stearate 190mg;

[0060] The preparation method of the above composition comprises the following steps:

[0061] 1) Weigh the raw materials of the formula respectively, select and weigh the auxiliary materials of the formula, and set aside;

[0062] 2) Pass betaine through a 30-mesh sieve, and mix zinc gluconate, vitamin B2, vitamin B6, 6s-5-methyltetrahydrofolate calcium, taurine, rice bran fatty alkyl alcohol, cystathionine-β-synthase, vitamin B1 and vitamin B 12 Mix them into compound raw materials and pass them through a 60-mesh sieve, and pass the auxiliary materials through a 30-mesh sieve for later use;

[0063] 3) premixing the sieved betaine with the composite raw materials to obtain mixed powder A;

[0064] 4) Mixing the mixed powder A with the sieved auxiliary materials to obtain a total mixed powder, packaging the total mixed powder and loading it into an oral solid pharmaceutical high-density polyethylene bottle to obtain a composition for reducing homocysteine.

[0065] Test Example 1

[0066] The composition obtained in Example 1 was tested for physical and chemical properties, and the statistical results are as follows:

[0067] 1. Sensory requirements: The contents are yellow; no peculiar smell; the capsule is complete and smooth, the contents are powder, and there are no foreign impurities visible to normal vision.

[0068] 2. Physical and chemical indicators: Statistical test values ​​and related standards are shown in Table 1 below.

[0069] Table 1 Physical and chemical indicators

[0070] project Detection value index Detection Methods Moisture, g / 100g 8.0±1.0 ≤9.0 GB5009.3 Ash content, g / 100g 3.2±0.7 ≤7.0 GB5009.4 Disintegration time, min 27±2.0 ≤30 Pharmacopoeia of the People's Republic of China Lead (Pb), mg / kg - ≤2.0 GB5009.12 Total arsenic (As), mg / kg - ≤1.0 GB5009.11 Total mercury (Hg), mg / kg - ≤0.3 GB5009.17 Hexachlorocyclohexane, mg / kg - ≤0.1 GB / T5009.19 DDT, mg / kg - ≤0.1 GB / T5009.19

[0071] 3. Microbiological indicators: Statistical test values ​​are shown in Table 2 below.

[0072] Table 2 Microbiological indicators

[0073] project Statistics index Detection Methods Total colony count, CFU / g 9800±200 ≤30000 GB4789.2 Coliform group, MPN / g 0.2±0.1 ≤0.92 GB4789.3MPN counting method Mold and yeast, CFU / g 17±1.3 ≤50 GB4789.15 Staphylococcus aureus - ≤0 / 25g GB4789.10 salmonella - ≤0 / 25g GB4789.4

[0074] Test Example 2

[0075] Animal Experiment Evaluation Methods

[0076] 1. Experimental principle: Methionine Met generates S-adenosylmethionine (SAM) under the catalysis of methionine adenosyltransferase (MAT) and the participation of ATP. SAM transfers methyl groups to DNA, RNA, protein and other molecules through methyltransferases (DNMTs) to form S-adenosylhomocysteine ​​(SAH), which is then hydrolyzed by SAH hydrolase (SAHH) to remove adenosine to generate Hcy, which can lead to the occurrence of diseases.

[0077] 2. Experimental methods:

[0078] 2.1 Experimental animals: Male rats weighing 200±20 g were selected and divided into five groups, with 10 rats in each group.

[0079] 2.2. Dosage groups and administration time of test samples: The experiment set up a blank control group, a model control group and three dosage groups of the test sample (the composition of Example 1). The first dosage group (0.133 g / kg) was 4 times the recommended daily dose for humans (2 g / 60 kg), the second dosage group (0.267 g / kg) was 8 times the recommended daily dose for humans, and the third dosage group (1.067 g / kg) was 16 times the recommended daily dose for humans. The test samples were administered for 30 days.

[0080] 3. Experimental steps:

[0081] After 1 week of adaptive feeding, the rats were randomly divided into 5 groups, 10 rats / group. On the first day of the experiment, blood was drawn to detect the plasma homocysteine ​​level of each group before the experiment. During the experiment, the blank control group was fed with ordinary feed, and the model control group and each dose group of the test sample were fed with 2% methionine feed to establish a hyperhomocysteinemia rat model. While modeling, each dose group of the test sample was orally gavaged with the corresponding dose of the composition of Example 1 every day, and the blank control group and the model control group were given an equal volume of normal saline, with a gavage dose of 1 ml / 100 g body weight, for 30 days. After the last administration, the rats were fasted but not watered for 12 hours, weighed, anesthetized with 1% sodium pentobarbital, blood was drawn, liver was taken, and liver SAM level, plasma and liver homocysteine ​​levels were measured;

[0082] Plasma Hcy: Separate plasma from heparinized whole blood, centrifuge at 2000 rpm for 15 min, and store at -30°C;

[0083] Liver Hcy, SAM: The whole liver was quickly removed, rinsed with ice saline, blotted dry on filter paper, cut into two parts, weighed, quickly frozen in liquid nitrogen, and stored at -80°C.

[0084] 4. Experimental results

[0085] 4.1. Plasma homocysteine ​​levels in rats

[0086] Table 3 Plasma homocysteine ​​levels

[0087]

[0088] Compared with the blank group, aaa P<0.001, compared with the model group, bb P<0.01, bbb P<0.001

[0089] From Table 3 and Figure 1The results show that compared with the blank control group, the plasma Hcy level of the model control group was significantly increased, and the difference was significant (P<0.001), and the model was established; compared with the model control group, the plasma Hcy level of each dose group was reduced, and the difference was significant (P<0.01, P<0.001), which can be determined that the composition of Example 1 is helpful to improve homocysteine ​​metabolism and reduce homocysteine ​​levels, and the higher the dose, the better the reduction effect.

[0090] 4.2. Homocysteine ​​and SAM Levels in Rat Liver

[0091] From Table 4 and Figure 2-3 The results show that compared with the blank control group, the model control group had increased liver Hcy and liver SAM levels, and the difference was significant (P<0.001). Compared with the model control group, the liver Hcy and liver SAM levels of each dose group were decreased, and the difference was significant (P<0.01, P<0.001). This shows that the composition of Example 1 helps to improve homocysteine ​​metabolism and reduce the levels of homocysteine ​​and the intermediate product SAM, and the higher the dose, the better the reduction effect.

[0092] Table 4 Liver homocysteine ​​and SAM levels

[0093]

[0094] Compared with the blank group, aaa P<0.001, compared with the model group, bb P<0.01, bbb P<0.001

[0095] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A composition for reducing homocysteine, characterized in that: The composition comprises the following raw materials by weight: 1300-1800 parts of betaine, 80-90 parts of zinc gluconate, 14-18 parts of vitamin B2, 6-10 parts of vitamin B6, 0.1-1 parts of 6S-5-methyltetrahydrofolate calcium, and 100 parts of vitamin B6. 12 0.001-0.01 parts, taurine 1-6 parts, rice bran fatty alkanol 2-4 parts, vitamin B13-7 parts, cystathionine-β-synthase 0.001-0.01 parts; The composition further comprises 180-190 parts of auxiliary materials; The auxiliary material is selected from one or more of polyvinyl pyrrolidone, hydroxypropyl methylcellulose, magnesium stearate, sucrose, mannitol and cellulose acetate.

2. The composition according to claim 1, characterized in that The composition comprises the following raw materials by weight: 1500 parts of betaine, 87.66 parts of zinc gluconate, 16 parts of vitamin B2, 8 parts of vitamin B6, 0.451 parts of 6S-5-methyltetrahydrofolate calcium, and 0.5 parts of vitamin B6. 12 0.008 parts, taurine 3 parts, rice bran fatty alkanol 3 parts, vitamin B15 parts, cystathionine-β-synthase 0.005 parts; The composition further comprises 187.881 parts of auxiliary materials.

3. The composition according to claim 1, characterized in that The dosage form of the composition includes capsules and tablets.

4. The method for preparing the composition for reducing homocysteine ​​according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: 1) Weigh the raw materials of the formula respectively, select and weigh the auxiliary materials of the formula, and set aside; 2) Screen the betaine, and separate the zinc gluconate, vitamin B2, vitamin B6, 6S-5-methyltetrahydrofolate calcium, taurine, rice bran fatty alkyl alcohol, cystathionine-β-synthase, vitamin B1 and vitamin B 12 Mix them into compound raw materials and sieve them, and sieve the auxiliary materials for later use; 3) premixing the sieved betaine with the composite raw materials to obtain mixed powder A; 4) Mixing the mixed powder A with the sieved auxiliary materials to obtain a total mixed powder, and packaging and bottling the total mixed powder to obtain the composition for reducing homocysteine.

5. The method for preparing the composition for reducing homocysteine ​​according to claim 4, characterized in that: The method is carried out in a 100,000-class clean area.

6. The method for preparing the composition for reducing homocysteine ​​according to claim 4, characterized in that: In step 2), the mesh number of the betaine sieved is 30-50 mesh, the mesh number of the composite raw material sieved is 60-80 mesh, and the mesh number of the auxiliary material sieved is 30-50 mesh.

7. The method for preparing the composition for reducing homocysteine ​​according to claim 4, characterized in that: In step 3), the weight ratio of betaine to the compound raw material in the mixed powder A is 10-15:

1.

8. The method for preparing the composition for reducing homocysteine ​​according to claim 4, characterized in that: In step 4), the total mixed powder is bottled in oral solid pharmaceutical high-density polyethylene bottles.

Images